Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM).

MATERIALS AND METHODS: Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score.

RESULTS: In 66 patients eligible for IHC, the H-score was ≥upper quartile in 21 (RRM1-positive) and <upper quartile (RRM1-negative) in 45 cases. The long-term (2-year) survival rate for patients with RRM1-negative MPM in the CiV-treated group was significantly superior to that for patients with RRM1-positive MPM (47% versus 13%, p=0.002). No difference occurred in the CaP-treated group.

CONCLUSION: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC.

Original languageEnglish
JournalAnticancer Research
Volume35
Issue number12
Pages (from-to)6731-8
Number of pages8
ISSN0250-7005
Publication statusPublished - Dec 2015

ID: 46023259